DNA Methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Selamat, Suhaida A ^a   Galler, Janice S ^a   Joshi, Amit D ^b   Fyfe, M Nicky ^c   Campan, Mihaela ^a   Siegmund, Kimberly D ^b   Kerr, Keith M ^c   Laird Offringa, Ite A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEUROGENIC DIFFERENTIATION FACTOR; ONCOPROTEIN; PROTEIN 2C35; PROTEIN CDH13; PROTEIN EYA4; PROTEIN HOXA1; PROTEIN HOXA11; PROTEIN NEUROD2; PROTEIN OPCML; PROTEIN PTPRN2; PROTEIN RASSF1; PROTEIN TMEFF2; PROTEIN TWIST1; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; UNCLASSIFIED DRUG;

2C35 GENE; ARTICLE; CANCER DIAGNOSIS; CARCINOMA IN SITU; CDH13 GENE; CDKN2A GENE; CDX2 GENE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA PROBE; EYA4 GENE; GENE LOCUS; HISTOPATHOLOGY; HOXA1 GENE; HOXA11 GENE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG CARCINOGENESIS; NEUROD1 GENE; NEUROD2 GENE; ONCOGENE; OPCML GENE; PTPRN2 GENE; RASSF1 GENE; REAL TIME POLYMERASE CHAIN REACTION; SECRETED FRIZZLED RELATED PROTEIN 1 GENE; TMEFF2 GENE; TWIST1 GENE; ADENOCARCINOMA; ADENOMA; GENETICS; HYPERPLASIA; LUNG; LUNG TUMOR; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; ADENOMA; DNA METHYLATION; GENETIC LOCI; HUMANS; HYPERPLASIA; LUNG; LUNG NEOPLASMS; PRECANCEROUS CONDITIONS;

EID: 79959568138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021443     Document Type: Article

References (104)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, et al. (2007) Global Cancer Facts & Figures 2007. Atlanta, GA American Cancer Society.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
3. Jemal A, Center MM, DeSantis C, Ward EM, (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
4. Horner MJ, Ries LAG KM, Neyman N, Aminou R, et al. (2009) SEER Cancer Statistics Review, 1975-2006 Bethesda, MD http://seercancergov/csr/1975_2006/.
5. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, et al. (2003) Lung cancer screening with CT: Mayo Clinic experience. Radiology 226: 756-761.
6. (2010) The National Lung Screening Trial: Overview and Study Design. Radiology.
7. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, et al. (2007) Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 120: 868-874.
8. Black WC, (2000) Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 92: 1280-1282.
9. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA, (2007) The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers 23: 5-30.
10. Belinsky SA, (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer 4: 1-11.
11. Anglim PP, Alonzo TT, Laird-Offringa IA, (2008) DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 7: 81.
12. Laird PW, (2010) Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 11: 191-203.
13. Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, et al. (2008) DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res in press.
14. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
15. Au JS, Mang OW, Foo W, Law SC, (2004) Time trends of lung cancer incidence by histologic types and smoking prevalence in Hong Kong 1983-2000. Lung Cancer 45: 143-152.
16. Chen F, Cole P, Bina WF, (2007) Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 16: 2724-2729.
17. Koyi H, Hillerdal G, Branden E, (2002) A prospective study of a total material of lung cancer from a county in Sweden 1997-1999: gender, symptoms, type, stage, and smoking habits. Lung Cancer 36: 9-14.
18. Tse LA, Mang OW, Yu IT, Wu F, Au JS, et al. (2009) Cigarette smoking and changing trends of lung cancer incidence by histological subtype among Chinese male population. Lung Cancer 66: 22-27.
19. Harkness EF, Brewster DH, Kerr KM, Fergusson RJ, MacFarlane GJ, (2002) Changing trends in incidence of lung cancer by histologic type in Scotland. Int J Cancer 102: 179-183.
20. Scagliotti GV, Longo M, Novello S, (2009) Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 21: 99-104.
21. Chapman AD, Kerr KM, (2000) The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 83: 632-636.
22. Westra WH, (2000) Early glandular neoplasia of the lung. Respir Res 1: 163-169.
23. Kerr KM, (2001) Pulmonary preinvasive neoplasia. J Clin Pathol 54: 257-271.
24. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
25. Travis WD, Colby TV, Corrin B, (1999) Histological Typing of Lung Cancer and Pleural Tumors. editors. WHO International Histological Classification of Tumors, 3rd edition 29- Berlin Springer.
26. Funama Y, Awai K, Liu D, Oda S, Yanaga Y, et al. (2009) Detection of nodules showing ground-glass opacity in the lungs at low-dose multidetector computed tomography: phantom and clinical study. J Comput Assist Tomogr 33: 49-53.
27. Ikeda K, Awai K, Mori T, Kawanaka K, Yamashita Y, et al. (2007) Differential diagnosis of ground-glass opacity nodules: CT number analysis by three-dimensional computerized quantification. Chest 132: 984-990.
28. Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, et al. (2001) Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 159: 1941-1948.
29. Morandi L, Asioli S, Cavazza A, Pession A, Damiani S, (2007) Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung. Lung Cancer 56: 35-42.
30. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, et al. (2007) Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 212: 287-294.
31. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
32. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
33. Tanaka K, Okamoto A, (2007) Degradation of DNA by bisulfite treatment. Bioorg Med Chem Lett 17: 1912-1915.
34. Licchesi JD, Westra WH, Hooker CM, Herman JG, (2008) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14: 2570-2578.
35. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, et al. (2008) Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29: 895-904.
36. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, et al. (2007) Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 6: 70.
37. Dammann R, Li C, Yoon J-H, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nature Genet 25: 315-319.
38. Ehrlich M, (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
39. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of Repetitive Element DNA Methylation by MethyLight. Nucleic Acids Res 33: 6823-6836.
40. Campan M, Weisenberger DJ, Trinh B, Laird PW, (2009) MethyLight. Methods Mol Biol 507: 325-337.
41. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, et al. (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17: 3208-3215.
42. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
43. Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, et al. (2001) Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia 3: 314-323.
44. Costello JC, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, et al. (2000) Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nature Genet 25: 132-138.
45. Zeger SL, Liang KY, (1992) An overview of methods for the analysis of longitudinal data. Stat Med 11: 1825-1839.
46. Kaufman L, Rousseuw PJ, (1990) Finding Groups in Data: An Introduction to Cluster Analysis. New York Wiley Interscience.
47. Guo M, House MG, Hooker C, Han Y, Heath E, et al. (2004) Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 10: 5131-5136.
48. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. (2006) CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45: 781-789.
49. Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM, (2005) Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 18: 170-178.
50. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, et al. (2010) Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch.
51. Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, et al. (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 12: R3.
52. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y, (1994) Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202: 1426-1430.
53. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
54. Belinsky SA, (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26: 1481-1487.
55. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. (1998) Aberrant methylation of p16 INK4a is an early event in lung cancer and potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896.
56. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG, (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96: 12754-12759.
57. Nguyen CT, Gonzales FA, Jones PA, (2001) Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 29: 4598-4606.
58. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, et al. (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
59. Kawasaki E, Eisenbarth GS, Wasmeier C, Hutton JC, (1996) Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes. Overlapping specificities to phogrin and ICA512/IA-2. Diabetes 45: 1344-1349.
60. Takeyama N, Ano Y, Wu G, Kubota N, Saeki K, et al. (2009) Localization of insulinoma associated protein 2, IA-2 in mouse neuroendocrine tissues using two novel monoclonal antibodies. Life Sci 84: 678-687.
61. Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, et al. (2010) Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 119: 157-175.
62. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, et al. (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304: 1164-1166.
63. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
64. Anglim PA, Galler JS, Koss MN, Hagen JA, Turla S, et al. (2008) Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 7: 62.
65. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL, (2004) GenBank: update. Nucleic Acids Res 32: D23-6.
66. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ, et al. (2004) Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 36: 1301-1305.
67. Consortium ENCODE (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
68. Zou H, Osborn NK, Harrington JJ, Klatt KK, Molina JR, et al. (2005) Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 14: 830-834.
69. Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y, (2002) HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene 21: 3659-3662.
70. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 104: 5527-5532.
71. Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, et al. (2004) DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep 12: 177-180.
72. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, et al. (2004) RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64: 3137-3143.
73. Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, et al. (2008) DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22: 1035-1043.
74. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, et al. (2008) Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 14: 3494-3502.
75. Naya FJ, Huang HP, Qiu Y, Mutoh H, DeMayo FJ, et al. (1997) Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. Genes Dev 11: 2323-2334.
76. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A, (1998) The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 103: 96-101.
77. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, et al. (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung cancer. Cancer Res 61: 4556-4560.
78. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF, (2004) Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100: 1472-1477.
79. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, et al. (2003) Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153-160.
80. Ulivi P, Zoli W, Calistri D, Fabbri F, Tesei A, et al. (2006) p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 206: 611-615.
81. Kim JS, Han J, Shim YM, Park J, Kim DH, (2005) Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 104: 1825-1833.
82. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, et al. (2006) Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106: 2200-2207.
83. Zhong Y, Delgado Y, Gomez J, Lee SW, Perez-Soler R, (2001) Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity. Clin Cancer Res 7: 1683-1687.
84. Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, et al. (2007) Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9: 840-852.
85. Maneckjee R, Minna JD, (1990) Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A 87: 3294-3298.
86. Wang L, Zhu JS, Song MQ, Chen GQ, Chen JL, (2006) Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. World J Gastroenterol 12: 6949-6954.
87. Fukui T, Kondo M, Ito G, Maeda O, Sato N, et al. (2005) Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24: 6323-6327.
88. Zhang YW, Miao YF, Yi J, Geng J, Wang R, et al. (2010) Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma 57: 228-233.
89. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, et al. (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62.
90. Shames DS, Girard L, Gao B, Sato M, Lewis CM et al, (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486.
91. Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MJ, et al. (2004) Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 10: 3104-3109.
92. Yuen HF, Chan YP, Wong ML, Kwok WK, Chan KK, et al. (2007) Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60: 510-514.
93. Niu RF, Zhang L, Xi GM, Wei XY, Yang Y, et al. (2007) Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 26: 385-394.
94. Baba Y, Nosho K, Shima K, Freed E, Irahara N, et al. (2009) Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15: 4665-4673.
95. Kawai H, Tomii K, Toyooka S, Yano M, Murakami M, et al. (2005) Promoter methylation downregulates CDX2 expression in colorectal carcinomas. Oncol Rep 13: 547-551.
96. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, et al. (2002) Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 8: 2362-2368.
97. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, et al. (2002) Methylation of the RASSF1A gene in human cancers. Biol Chem 383: 907-914.
98. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, et al. (2001) DNA methylation profiles of lung tumors. Mol Cancer Therap 1: 61-67.
99. Kim DH, Kim JS, Ji YI, Shim YM, Kim H, et al. (2003) Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63: 3743-3746.
100. Niklinska W, Naumnik W, Sulewska A, Kozlowski M, Pankiewicz W, et al. (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 47: 275-280.
101. Hobbs M, Mattick JS, (1993) Common components in the assembly of type 4 fimbriae, DNA transfer systems, filamentous phage and protein-secretion apparatus: a general system for the formation of surface-associated protein complexes. Mol Microbiol 10: 233-243.
102. Anisowicz A, Huang H, Braunschweiger KI, Liu Z, Giese H, et al. (2008) A high-throughput and sensitive method to measure global DNA methylation: application in lung cancer. BMC Cancer 8: 222.
103. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP, (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58: 5489-5494.
104. Shimada A, Kano J, Ishiyama T, Okubo C, Iijima T, et al. (2005) Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 96: 668-675.